HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hepatic fibrosis with hepatic sclerosis — Clinical Guidelines

Overview

Hepatic fibrosis with hepatic sclerosis refers to the excessive accumulation of extracellular matrix proteins in the liver, leading to organ dysfunction. This condition often progresses from chronic liver diseases such as cirrhosis and can result in portal hypertension and impaired liver function.

Diagnosis

Imaging Studies: Ultrasound, CT, MRI can reveal characteristic changes indicative of fibrosis and sclerosis 3.

Laboratory Tests: Elevated levels of liver enzymes (ALT, AST), bilirubin, and decreased albumin levels may suggest advanced fibrosis 11.

Serum Biomarkers: Indocyanine green clearance can be used to assess hepatic function and detect early dysfunction 11.

Histopathological Evaluation: Liver biopsy remains the gold standard for grading the degree of fibrosis 4.

Management

Treatment of Underlying Cause: Addressing the primary liver disease (e.g., viral hepatitis, alcohol abuse) is crucial 4.

Medications:

- Tolvaptan: Monitor closely due to potential hepatic adverse effects; dose adjustments based on patient response and liver function 2. - Octreotide: Used palliatively for symptomatic relief in hepatic metastases, though evidence is limited 5.

Ablation Techniques: Radiofrequency ablation (RFA) and cryoablation (CRA) are options for managing hepatocellular carcinoma and metastases, with CRA showing comparable efficacy and safety to RFA 1.

Special Populations

Pregnancy: Hepatic rupture is a rare but severe complication; prompt surgical intervention is necessary 9.

Comorbidities: Patients with concurrent conditions like sepsis (e.g., neutropenic sepsis in lymphoma) require multidisciplinary care 6 14.

Key Recommendations

Liver Biopsy for Grading: Perform liver biopsy to accurately assess and grade the degree of fibrosis 4 (Evidence: Strong).

Monitor Tolvaptan Use: Closely monitor patients on tolvaptan for signs of hepatic adverse events due to its rare but serious side effects 2 (Evidence: Moderate).

Address Underlying Disease: Prioritize treatment of the underlying liver disease to halt progression of fibrosis 4 (Evidence: Strong).

Consider Ablation for HCC: Radiofrequency ablation or cryoablation can be effective for treating hepatocellular carcinoma, with CRA showing comparable outcomes to RFA 1 (Evidence: Moderate).

Palliative Care with Octreotide: Use octreotide cautiously for symptomatic relief in hepatic metastases, acknowledging limited evidence 5 (Evidence: Weak).

References

1 Huang X, Xu X, Du H, Sun Q, Wu M. Meta-analysis of cryoablation versus radiofrequency ablation in the treatment of malignant liver tumors. International journal of hyperthermia : the official journal of European Society for Hyperthermic Oncology, North American Hyperthermia Group 2024. link 2 Uno T, Hosomi K, Yokoyama S. Evaluation of tolvaptan-associated hepatic disorder using different national pharmacovigilance databases. Scientific reports 2024. link 3 Paulet E, Aubé C, Pessaux P, Lebigot J, Lhermitte E, Oberti F et al.. Factors limiting complete tumor ablation by radiofrequency ablation. Cardiovascular and interventional radiology 2008. link 4 Sun W, He F. Applications of proteomics in hepatic diseases research. Science in China. Series C, Life sciences 2004. link 5 Pistevou-Gombaki K, Eleftheriadis N, Plataniotis GA, Sofroniadis I, Kouloulias VE. Octreotide for palliative treatment of hepatic metastases from non-neuroendocrine primary tumours: evaluation of quality of life using the EORTC QLQ-C30 questionnaire. Palliative medicine 2003. link 6 Chim CS, Choy C, Ooi GC, Liang R. Primary hepatic lymphoma. Leukemia & lymphoma 2001. link 7 Lynch CJ, McCall KM, Ng YC, Hazen SA. Glucagon stimulation of hepatic Na(+)-pump activity and alpha-subunit phosphorylation in rat hepatocytes. The Biochemical journal 1996. link 8 Yohannan MD, Abdulla AM, Patel PJ. Neonatal hepatic haemangioendothelioma: presentation with jaundice and microangiopathic haemolytic anaemia. European journal of pediatrics 1990. link 9 Neerhof MG, Zelman W, Sullivan T. Hepatic rupture in pregnancy. Obstetrical & gynecological survey 1989. link 10 Harano Y, Kashiwagi A, Kojima H, Suzuki M, Hashimoto T, Shigeta Y. Phosphorylation of carnitine palmitoyltransferase and activation by glucagon in isolated rat hepatocytes. FEBS letters 1985. link80385-9) 11 Gottlieb ME, Stratton HH, Newell JC, Shah DM. Indocyanine green. Its use as an early indicator of hepatic dysfunction following injury in man. Archives of surgery (Chicago, Ill. : 1960) 1984. link 12 Andus T, Gross V, Tran-Thi TA, Schreiber G, Nagashima M, Heinrich PC. The biosynthesis of acute-phase proteins in primary cultures of rat hepatocytes. European journal of biochemistry 1983. link 13 Pearce W, Dunn EL, Moore EE. Hepatic artery ligation for delayed hepatic hemorrhage. Archives of surgery (Chicago, Ill. : 1960) 1980. link 14 Chambers TJ, O'Donoghue DP, Stansfeld AG. A case of primary lymphoma of the liver. Journal of clinical pathology 1976. link 15 Albritton WL, Levin AP. Aminotransferase from a deletion mutant in the histidine operon. Journal of bacteriology 1972. link

Hepatic fibrosis with hepatic sclerosis